Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Are PrP(C)s involved in some human myelin diseases? Relating experimental studies to human pathology.

Veber D, Scalabrino G.

J Neurol Sci. 2015 Dec 15;359(1-2):396-403. doi: 10.1016/j.jns.2015.09.365. Epub 2015 Oct 23. Review.

PMID:
26478128
2.

Low levels of cobalamin, epidermal growth factor, and normal prions in multiple sclerosis spinal cord.

Scalabrino G, Veber D, De Giuseppe R, Roncaroli F.

Neuroscience. 2015 Jul 9;298:293-301. doi: 10.1016/j.neuroscience.2015.04.020. Epub 2015 Apr 16.

PMID:
25888933
3.

Relationships between cobalamin, epidermal growth factor, and normal prions in the myelin maintenance of central nervous system.

Scalabrino G, Veber D, Tredici G.

Int J Biochem Cell Biol. 2014 Oct;55:232-41. doi: 10.1016/j.biocel.2014.09.011. Epub 2014 Sep 17. Review.

PMID:
25239885
4.

Myelin damage due to local quantitative abnormalities in normal prion levels: evidence from subacute combined degeneration and multiple sclerosis.

Scalabrino G, Veber D.

J Neurol. 2014 Aug;261(8):1451-60. doi: 10.1007/s00415-013-7152-3. Epub 2013 Oct 20. Review.

PMID:
24141733
5.

Cobalamin and normal prions: a new horizon for cobalamin neurotrophism.

Scalabrino G, Veber D.

Biochimie. 2013 May;95(5):1041-6. doi: 10.1016/j.biochi.2013.01.002. Epub 2013 Jan 15. Review.

PMID:
23328344
6.

Normal prions as a new target of cobalamin (vitamin B12) in rat central nervous system.

Scalabrino G, Veber D.

Clin Chem Lab Med. 2013 Mar 1;51(3):601-6. doi: 10.1515/cclm-2012-0474. Review.

PMID:
23183750
7.

Cobalamin as a regulator of serum and cerebrospinal fluid levels of normal prions.

Scalabrino G, Veber D, Briani C, Milani S, Terralavoro A, Brenna S, Valenti L, Silani V, Morelli C, Peracchi M.

J Clin Neurosci. 2013 Jan;20(1):134-8. doi: 10.1016/j.jocn.2012.08.004. Epub 2012 Nov 10.

PMID:
23146213
8.

Cobalamin (vitamin B(12)) regulation of PrP(C), PrP(C)-mRNA and copper levels in rat central nervous system.

Scalabrino G, Veber D, Mutti E, Calligaro A, Milani S, Tredici G.

Exp Neurol. 2012 Jan;233(1):380-90. doi: 10.1016/j.expneurol.2011.11.003. Epub 2011 Nov 12.

PMID:
22116041
9.

Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.

Hoveyda HR, Marsault E, Gagnon R, Mathieu AP, Vézina M, Landry A, Wang Z, Benakli K, Beaubien S, Saint-Louis C, Brassard M, Pinault JF, Ouellet L, Bhat S, Ramaseshan M, Peng X, Foucher L, Beauchemin S, Bhérer P, Veber DF, Peterson ML, Fraser GL.

J Med Chem. 2011 Dec 22;54(24):8305-20. doi: 10.1021/jm2007062. Epub 2011 Nov 22.

PMID:
22106937
10.

The octapeptide repeat PrP(C) region and cobalamin-deficient polyneuropathy of the rat.

Scalabrino G, Mutti E, Veber D, Rodriguez Menendez V, Novembrino C, Calligaro A, Tredici G.

Muscle Nerve. 2011 Dec;44(6):957-67. doi: 10.1002/mus.22225.

PMID:
22102467
11.

Cobalamin deficiency-induced changes of epidermal growth factor (EGF)-receptor expression and EGF levels in rat spinal cord.

Mutti E, Magnaghi V, Veber D, Faroni A, Pece S, Di Fiore PP, Scalabrino G.

Brain Res. 2011 Feb 28;1376:23-30. doi: 10.1016/j.brainres.2010.12.056. Epub 2010 Dec 23.

PMID:
21185268
12.

Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis.

Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E.

Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.

PMID:
20347721
13.

Factors that influence oral bioavailability; a cathepsin K inhibitor for human studies.

Veber DF.

Adv Exp Med Biol. 2009;611:607-10. No abstract available.

PMID:
19400330
14.

Cobalamin deficiency-induced changes in magnetic resonance imaging of cerebrospinal fluid volume in the cervical tract in the rat.

Veber D, Mutti E, Sironi L, Guerrini U, Gianazza E, Scalabrino G.

Neurosci Lett. 2008 Aug 8;440(3):202-5. doi: 10.1016/j.neulet.2008.05.079. Epub 2008 May 24.

PMID:
18571320
15.

Experimental and clinical evidence of the role of cytokines and growth factors in the pathogenesis of acquired cobalamin-deficient leukoneuropathy.

Scalabrino G, Veber D, Mutti E.

Brain Res Rev. 2008 Nov;59(1):42-54. doi: 10.1016/j.brainresrev.2008.05.001. Epub 2008 May 9. Review.

PMID:
18538413
16.

New pathogenesis of the cobalamin-deficient neuropathy.

Scalabrino G, Veber D, Mutti E.

Med Secoli. 2007;19(1):9-18.

PMID:
18447164
17.

Indirect down-regulation of nuclear NF-kappaB levels by cobalamin in the spinal cord and liver of the rat.

Veber D, Mutti E, Tacchini L, Gammella E, Tredici G, Scalabrino G.

J Neurosci Res. 2008 May 1;86(6):1380-7. doi: 10.1002/jnr.21599.

PMID:
18183619
18.

Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore.

Marino JP Jr, Fisher PW, Hofmann GA, Kirkpatrick RB, Janson CA, Johnson RK, Ma C, Mattern M, Meek TD, Ryan MD, Schulz C, Smith WW, Tew DG, Tomazek TA Jr, Veber DF, Xiong WC, Yamamoto Y, Yamashita K, Yang G, Thompson SK.

J Med Chem. 2007 Aug 9;50(16):3777-85. Epub 2007 Jul 18.

PMID:
17636946
19.

Cobalamin deficiency-induced down-regulation of p75-immunoreactive cell levels in rat central nervous system.

Mutti E, Veber D, Stampachiacchiere B, Triaca V, Gammella E, Tacchini L, Aloe L, Scalabrino G.

Brain Res. 2007 Jul 9;1157:92-9. Epub 2007 Apr 25. Erratum in: Brain Res. 2008 Jan 23;1190:225. Stampachiacchere, Barbara [corrected to Stampachiacchiere, Barbara].

PMID:
17524373
20.

Cobalamin-mediated regulation of transcobalamin receptor levels in rat organs.

Kalra S, Ahuja R, Mutti E, Veber D, Seetharam S, Scalabrino G, Seetharam B.

Arch Biochem Biophys. 2007 Jul 1;463(1):128-32. Epub 2007 Apr 2.

PMID:
17442257
21.

A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.

Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang SM, Tomaszek T, Yamashita DS, Marquis RW, Oh H, Jeong JU, Veber DF, Gowen M, Lark MW, Stroup G.

Bone. 2007 Jan;40(1):122-31. Epub 2006 Sep 7.

PMID:
16962401
22.

Increased levels of the CD40:CD40 ligand dyad in the cerebrospinal fluid of rats with vitamin B12(cobalamin)-deficient central neuropathy.

Veber D, Mutti E, Galmozzi E, Cedrola S, Galbiati S, Morabito A, Tredici G, La Porta CA, Scalabrino G.

J Neuroimmunol. 2006 Jul;176(1-2):24-33. Epub 2006 May 22.

PMID:
16716410
23.

Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.

Yamashita DS, Marquis RW, Xie R, Nidamarthy SD, Oh HJ, Jeong JU, Erhard KF, Ward KW, Roethke TJ, Smith BR, Cheng HY, Geng X, Lin F, Offen PH, Wang B, Nevins N, Head MS, Haltiwanger RC, Narducci Sarjeant AA, Liable-Sands LM, Zhao B, Smith WW, Janson CA, Gao E, Tomaszek T, McQueney M, James IE, Gress CJ, Zembryki DL, Lark MW, Veber DF.

J Med Chem. 2006 Mar 9;49(5):1597-612.

PMID:
16509577
24.

Increased spinal cord NGF levels in rats with cobalamin (vitamin B12) deficiency.

Scalabrino G, Mutti E, Veber D, Aloe L, Corsi MM, Galbiati S, Tredici G.

Neurosci Lett. 2006 Mar 27;396(2):153-8. Epub 2005 Dec 13.

PMID:
16352395
25.

Azepanone-based inhibitors of human cathepsin L.

Marquis RW, James I, Zeng J, Trout RE, Thompson S, Rahman A, Yamashita DS, Xie R, Ru Y, Gress CJ, Blake S, Lark MA, Hwang SM, Tomaszek T, Offen P, Head MS, Cummings MD, Veber DF.

J Med Chem. 2005 Nov 3;48(22):6870-8.

PMID:
16250645
26.

4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo.

Kallander LS, Lu Q, Chen W, Tomaszek T, Yang G, Tew D, Meek TD, Hofmann GA, Schulz-Pritchard CK, Smith WW, Janson CA, Ryan MD, Zhang GF, Johanson KO, Kirkpatrick RB, Ho TF, Fisher PW, Mattern MR, Johnson RK, Hansbury MJ, Winkler JD, Ward KW, Veber DF, Thompson SK.

J Med Chem. 2005 Sep 8;48(18):5644-7.

PMID:
16134930
27.

An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey.

Marquis RW, Ward KW, Roethke T, Smith BR, Ru Y, Yamashita DS, Tomaszek TA, Gorycki PD, Cheng HY, James IE, Stroup GB, Lark MW, Gowen M, Veber DF.

Mol Pharm. 2004 Jan 12;1(1):97-100. No abstract available.

PMID:
15832505
28.

Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors.

Yamashita DS, Xie R, Lin H, Wang B, Shi SD, Quinn CJ, Hemling ME, Hissong C, Tomaszek TA, Veber DF.

J Pept Res. 2004 Mar;63(3):265-9.

PMID:
15049838
29.

Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.

Widdowson KL, Elliott JD, Veber DF, Nie H, Rutledge MC, McCleland BW, Xiang JN, Jurewicz AJ, Hertzberg RP, Foley JJ, Griswold DE, Martin L, Lee JM, White JR, Sarau HM.

J Med Chem. 2004 Mar 11;47(6):1319-21.

PMID:
14998320
30.

Different uptake of cobalamin (vitamin B12) by astrocytes and oligodendrocytes isolated from rat spinal cord.

Buccellato FR, Foi L, Veber D, Pravettoni G, Scalabrino G.

Glia. 2004 Mar;45(4):406-11.

PMID:
14966871
31.

New basis of the neurotrophic action of vitamin B12.

Scalabrino G, Buccellato FR, Veber D, Mutti E.

Clin Chem Lab Med. 2003 Nov;41(11):1435-7. Review.

PMID:
14656022
32.

Cobalamin (vitamin B12)-deficiency-induced changes in the proteome of rat cerebrospinal fluid.

Gianazza E, Veber D, Eberini I, Buccellato FR, Mutti E, Sironi L, Scalabrino G.

Biochem J. 2003 Aug 15;374(Pt 1):239-46.

33.

Decreased GFAP-mRNA expression in spinal cord of cobalamin-deficient rats.

Magnaghi V, Veber D, Morabito A, Buccellato FR, Melcangi RC, Scalabrino G.

FASEB J. 2002 Nov;16(13):1820-2. Epub 2002 Sep 19.

PMID:
12354698
34.

Regulation of the ferritin H subunit by vitamin B12 (cobalamin) in rat spinal cord.

Cairo G, Ronchi R, Buccellato FR, Veber D, Santambrogio P, Scalabrino G.

J Neurosci Res. 2002 Jul 1;69(1):117-24.

PMID:
12111823
35.

Cobalamin (vitamin B(12)) positively regulates interleukin-6 levels in rat cerebrospinal fluid.

Scalabrino G, Corsi MM, Veber D, Buccellato FR, Pravettoni G, Manfridi A, Magni P.

J Neuroimmunol. 2002 Jun;127(1-2):37-43.

PMID:
12044973
36.

Molecular properties that influence the oral bioavailability of drug candidates.

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD.

J Med Chem. 2002 Jun 6;45(12):2615-23.

PMID:
12036371
37.

A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, Lechowska BA, Hoffman SJ, Smith BR, Kapadia R, Liang X, Erhard K, Ru Y, Dong X, Marquis RW, Veber D, Gowen M.

Bone. 2002 May;30(5):746-53.

PMID:
11996914
38.

Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.

Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M.

J Bone Miner Res. 2001 Oct;16(10):1739-46.

39.

Aspartic protease inhibitors: expedient synthesis of 2-substituted statines.

Travins JM, Bursavich MG, Veber DF, Rich DH.

Org Lett. 2001 Aug 23;3(17):2725-8.

PMID:
11506619
40.

Azepanone-based inhibitors of human and rat cathepsin K.

Marquis RW, Ru Y, LoCastro SM, Zeng J, Yamashita DS, Oh HJ, Erhard KF, Davis LD, Tomaszek TA, Tew D, Salyers K, Proksch J, Ward K, Smith B, Levy M, Cummings MD, Haltiwanger RC, Trescher G, Wang B, Hemling ME, Quinn CJ, Cheng HY, Lin F, Smith WW, Janson CA, Zhao B, McQueney MS, D'Alessio K, Lee CP, Marzulli A, Dodds RA, Blake S, Hwang SM, James IE, Gress CJ, Bradley BR, Lark MW, Gowen M, Veber DF.

J Med Chem. 2001 Apr 26;44(9):1380-95.

PMID:
11311061
41.

Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.

Dodds RA, James IE, Rieman D, Ahern R, Hwang SM, Connor JR, Thompson SD, Veber DF, Drake FH, Holmes S, Lark MW, Gowen M.

J Bone Miner Res. 2001 Mar;16(3):478-86.

42.

Cyclic ketone inhibitors of the cysteine protease cathepsin K.

Marquis RW, Ru Y, Zeng J, Trout RE, LoCastro SM, Gribble AD, Witherington J, Fenwick AE, Garnier B, Tomaszek T, Tew D, Hemling ME, Quinn CJ, Smith WW, Zhao B, McQueney MS, Janson CA, D'Alessio K, Veber DF.

J Med Chem. 2001 Mar 1;44(5):725-36.

PMID:
11262083
43.

Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro.

James IE, Marquis RW, Blake SM, Hwang SM, Gress CJ, Ru Y, Zembryki D, Yamashita DS, McQueney MS, Tomaszek TA, Oh HJ, Gowen M, Veber DF, Lark MW.

J Biol Chem. 2001 Apr 13;276(15):11507-11. Epub 2001 Jan 8. Erratum in: J Biol Chem. 2003 Aug 22;278(34):32484.

44.

The therapeutic potential of advances in cysteine protease inhibitor design.

Veber DF, Thompson SK.

Curr Opin Drug Discov Devel. 2000 Jul;3(4):362-9.

PMID:
19649868
45.

Solid-phase synthesis of a combinatorial array of 1,3-bis(acylamino)-2-butanones, inhibitors of the cysteine proteases cathepsins K and L.

Yamashita DS, Dong X, Oh HJ, Brook CS, Tomaszek TA, Szewczuk L, Tew DG, Veber DF.

J Comb Chem. 1999 May-Jun;1(3):207-15.

PMID:
10746010
46.

Mechanism of inhibition of cathepsin K by potent, selective 1, 5-diacylcarbohydrazides: a new class of mechanism-based inhibitors of thiol proteases.

Bossard MJ, Tomaszek TA, Levy MA, Ijames CF, Huddleston MJ, Briand J, Thompson S, Halpert S, Veber DF, Carr SA, Meek TD, Tew DG.

Biochemistry. 1999 Nov 30;38(48):15893-902.

PMID:
10625455
47.

Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K.

Duffy KJ, Ridgers LH, DesJarlais RL, Tomaszek TA, Bossard MJ, Thompson SK, Keenan RM, Veber DF.

Bioorg Med Chem Lett. 1999 Jul 19;9(14):1907-10.

PMID:
10450951
48.

Structure-based design of non-peptide, carbohydrazide-based cathepsin K inhibitors.

Thompson SK, Halbert SM, DesJarlais RL, Tomaszek TA, Levy MA, Tew DG, Ijames CF, Veber DF.

Bioorg Med Chem. 1999 Apr;7(4):599-605.

PMID:
10353639
49.

Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K.

Marquis RW, Ru Y, Yamashita DS, Oh HJ, Yen J, Thompson SK, Carr TJ, Levy MA, Tomaszek TA, Ijames CF, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, D'Alessio KJ, McQueney MS, Veber DF.

Bioorg Med Chem. 1999 Apr;7(4):581-8.

PMID:
10353637
50.

Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.

LaLonde JM, Zhao B, Smith WW, Janson CA, DesJarlais RL, Tomaszek TA, Carr TJ, Thompson SK, Oh HJ, Yamashita DS, Veber DF, Abdel-Meguid SS.

J Med Chem. 1998 Nov 5;41(23):4567-76.

PMID:
9804696

Supplemental Content

Support Center